JOB OPPORTUNITIES
Viroclinics Biosciences is a leader in the strongly growing and very dynamic market of diagnostic services companies. As a service organization we offer serological, virus-based and molecular analyses of any type of sample to assist our global customers with testing their antiviral drugs and vaccines. Our analyses encompass many types of viruses, including Influenza, RSV and Polio. Our rapidly growing company is now expanding its HBV Business Unit.
This expansion is part of our growth strategy and allows for hiring two new key leadership positions: a Director HBV Business Development and a Director HBV Services.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
OUR LATEST NEWS
The merger of Cerba Research and Viroclinics-DDL
After the acquisition of Viroclinics-DDL by the group Cerba Healthcare, we are delighted to announce that Cerba Research, the group’s global clinical trial central and speciality laboratory services division, has now merged with Viroclinics-DDL, a fast-growing global specialist virology and immunology contract research organisation (CRO).
Cerba Healthcare enters agreement to acquire Viroclinics-DDL expanding and transforming its offering in clinical trials
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has reached agreement to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO), from Summit Partners.
Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network
Today, Viroclinics-DDL, a global Contract Research Organization supporting clinical and preclinical studies for drug and vaccine development and CEPI, the Coalition for Epidemic Preparedness Innovations, signed an agreement which allows Viroclinics-DDL to produce and distribute laboratory stocks of the Omicron SARS-CoV-2 variant for use in CEPI’s centralised COVID-19 vaccine testing network. The produced Omicron SARS-COV-2 variant will be used for the performance of laboratory assays, assessing the neutralizing potential of COVID-19 vaccines against the new variant.
